Based on this YouTube video's total view count of 238K views and industry-standard rates, the estimated total earning is $167 - $477 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

Explore Excellent vaccine news with 238,369 views, 7,843 likes, and 3,496 comments. Experience the impact of this video content that has captured audience attention.

Pfizer progress 400 GPs, 83 hospitals Half a million so far 200,000 a day should be receiving jabs, well over one million a week by Christmas Pfizer orders 50 million doses by end of 2020 US, 100 – 500 million doses EU, 200 million doses UK, 40 million doses EMA, Monday 21st December Moderna FDA grants emergency approval Six million doses ready to go The end begins just after Christmas Approved within days of Christmas Senior Whitehall sources Medicines and Healthcare Regulatory Agency (MHRA) 28 or 29 December Final data provided to the regulator on Monday 21st December Four million doses ready Football stadia, racecourses, conference centres, pharmacies First week of January Several million doses a week UK, 100 million doses (80 million produced in UK) India, 50 million doses in stock First batch of four million doses, Netherlands and Germany AstraZeneca has 15 million doses of active ingredients ready, filled into vials in days Two doses, 4 week gap Leaving an adequate gap between doses is the most crucial way to boost efficacy Oxford AstraZeneca orders EU, 400 million doses UK, 100 million US, 300 million China, 200 million Japan, 120 million Brazil, 100 million Indonesia, 100 million Australia, 33.6 million Egypt 30 million Argentina 32 million Canada 20 million Argentina and Mexico to produce for Latin America Vaccines alliance for poorer countries, 300 million Three billion does in 2021 Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses, (Nature Medicine, 17th December) Viral vector coronavirus vaccine, ChAdOx1 nCoV-19 (AZD1222) https://www.nature.com/articles/s41591-020-01179-4 190 vaccines currently in development Neutralizing antibodies against the viral spike protein correlate with protection Additional antibody functions may also be important in preventing infection Two jabs, 56 days apart SD/SD n = 20 SD/LD n = 32 A booster dose is safe and better tolerated than priming doses After second dose Increased anti-spike neutralizing antibody titers, Increased cell mediated immunity Increased neutrophil and monocyte phagocytosis Increased complement activation Increased natural killer cell activation SD / SD Stronger antibody responses T cell responses did not increase with either booster dose These data support the two-dose vaccine regime that is now being evaluated in phase 3 clinical trials

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.